Literature DB >> 7717284

Provocation of latent left ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic cardiomyopathy.

T H Marwick1, S Nakatani, B Haluska, J D Thomas, H M Lever.   

Abstract

Amyl nitrite may be used to provoke latent gradients in patients with hypertrophic cardiomyopathy (HC) without significant resting outflow tract gradients, but afterload reduction may not be comparable to a more physiologic stressor such as symptom-limited exercise testing. This study compared the ability of amyl nitrite and exercise testing to provoke outflow tract gradients in 57 patients (40 men and 17 women, mean age +/- SD 49 +/- 16 years) with HC (septal thickness 19 +/- 5 mm, average resting gradient 13 +/- 10 mm Hg) who underwent echocardiography at rest, after amyl nitrite inhalation, and after maximal exercise. No significant gradient (< 50 mm Hg) was induced after either provocation in 26 patients (46%); in 15 patients (26%), inducibility was achieved after both stressors, in 6 (11%) after exercise only, and in 10 (18%) after amyl only. Patients with amyl-induced gradients differed from those in whom gradients were noninducible on the basis of smaller outflow tract dimensions (p < 0.001), larger resting gradients (p < 0.001), and a greater prevalence of "septal bulge" morphology (p = 0.02). Those with exercise-induced gradients were able to attain a greater workload (p = 0.07), have larger resting gradients (p = 0.02), and also tended to have a septal bulge morphology (p < or = 0.01). Although outflow tract obstruction increased to similar levels after amyl nitrite (49 +/- 39 mm Hg) and symptom-limited exercise (47 +/- 39 mm Hg), gradients induced by exercise and amyl correlated poorly (r = 0.54).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7717284     DOI: 10.1016/s0002-9149(99)80416-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Comparison of Outcomes in Patients With Nonobstructive, Labile-Obstructive, and Chronically Obstructive Hypertrophic Cardiomyopathy.

Authors:  Iraklis Pozios; Celia Corona-Villalobos; Lars L Sorensen; Paco E Bravo; Marco Canepa; Chiara Pisanello; Aurelio Pinheiro; Veronica L Dimaano; Hongchang Luo; Zeina Dardari; Xun Zhou; Ihab Kamel; Stefan L Zimmerman; David A Bluemke; M Roselle Abraham; Theodore P Abraham
Journal:  Am J Cardiol       Date:  2015-06-26       Impact factor: 2.778

Review 2.  Diagnosis and management of hypertrophic cardiomyopathy.

Authors:  Antonis Pantazis; Annina S Vischer; Maria Carrillo Perez-Tome; Silvia Castelletti
Journal:  Echo Res Pract       Date:  2015-03-11

3.  Association between severity of obstructive sleep apnea and high-sensitivity C-reactive protein in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Juan Wang; Haobo Xu; Chao Guo; Xin Duan; Fenghuan Hu; Weixian Yang; Jingang Cui; Lei Song; Yushi Chun; Jiansong Yuan; Shubin Qiao
Journal:  Clin Cardiol       Date:  2020-05-27       Impact factor: 2.882

4.  Clinical predictors of the presence of obstructive sleep apnea in patients with hypertrophic cardiomyopathy.

Authors:  Haobo Xu; Juan Wang; Jiansong Yuan; Chao Guo; Fenghuan Hu; Weixian Yang; Lei Song; Xiaoliang Luo; Rong Liu; Jingang Cui; Shengwen Liu; Yushi Chun; Yunhu Song; Shubin Qiao
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

5.  Provocation of left ventricular outflow tract obstruction using nitrate inhalation in hypertrophic cardiomyopathy: Relation to electromechanical delay.

Authors:  Hala Mahfouz Badran; Waleed Abdou Ibrahim; Naglaa Faheem; Rehab Yassin; Tamer Alashkar; Magdi Yacoub
Journal:  Glob Cardiol Sci Pract       Date:  2015-04-24

6.  Comparison of sublingual isosorbide dinitrate and Valsalva maneuver for detection of obstruction in hypertrophic cardiomyopathy.

Authors:  David Zemanek; Pavol Tomasov; Miloš Bělehrad; Katarína Hladká; Jana Košťálová; Tomáš Kára; Josef Veselka
Journal:  Arch Med Sci       Date:  2015-01-14       Impact factor: 3.318

7.  Acute effects of ivabradine on dynamic obstruction of the left ventricular outflow tract in cats with preclinical hypertrophic cardiomyopathy.

Authors:  K A Blass; K E Schober; X Li; B A Scansen; J D Bonagura
Journal:  J Vet Intern Med       Date:  2014-03-05       Impact factor: 3.333

8.  Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy.

Authors:  Dai-Yin Lu; Iraklis Pozios; Bereketeab Haileselassie; Ioannis Ventoulis; Hongyun Liu; Lars L Sorensen; Marco Canepa; Susan Phillip; M Roselle Abraham; Theodore P Abraham
Journal:  J Am Heart Assoc       Date:  2018-02-25       Impact factor: 5.501

9.  Implication of Apnea-Hypopnea Index, a Measure of Obstructive Sleep Apnea Severity, for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy.

Authors:  Haobo Xu; Juan Wang; Jiansong Yuan; Fenghuan Hu; Weixian Yang; Chao Guo; Xiaoliang Luo; Rong Liu; Jingang Cui; Xiaojin Gao; Yushi Chun; Shubin Qiao
Journal:  J Am Heart Assoc       Date:  2020-04-16       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.